MUSE Microscopy, Inc. is Entering a New Era of Digital Pathology

Digital pathology pioneer MUSE Microscopy, Inc. declared that it is nearing the end of its development. MUSE has persistently followed a visionary roadmap that has the potential to transform the future of digital pathology since being strategically acquired by the present leadership team in 2021. The industry's first tissue to digital™ imager, SmartPath MUSE TechnologyTM (SmartPath), uses MUSE (Microscopy with Ultraviolet Surface Excitation) technology to create a solution that does away with the need for traditional slide-based histology, a fundamental process that hasn't changed in over a century. Today, that journey reaches an exciting moment.

The goal of SmartPath's cutting-edge imager is to offer innovative technology that quickly takes high-resolution UV pictures straight from fresh or formalin-fixed (non-FFPE) tissue and transforms them into intricate digital images that resemble H&E for pathologists to analyze. The amount of RNA preserved in the sample for further processing is greatly increased when non-caustic fluorescent dyes are applied to fresh tissue. With the aim of providing pathologists at diagnostic pathology labs around the world with previously unheard-of efficiency, this first-of-its-kind imager employs a straightforward methodology. SmartPath has the potential to advance pathology into the digital era and assist a variety of international IVD applications and market areas by doing away with laborious manual operations.

"We are incredibly proud of the advancements we've made with SmartPath—a groundbreaking tissue-to-digital imager that redefines where true digital pathology starts," said Matthew Nuñez, CEO of MUSE Microscopy, Inc., expressing the company's excitement about this historic accomplishment. This moment symbolizes more than just a new product; it holds the potential to fundamentally revolutionize pathology as a whole, enabling experts to overcome antiquated methods that have hindered productivity and diagnostic improvements for far too long. We aim to establish a new benchmark with SmartPath and pave the way for the upcoming generation of pathology aids.

Transforming a Long-Standing Pathology Workflow

One of pathology's most enduring problems is the reliance on conventional glass slide histology, which the SmartPath Imager addresses. SmartPath aims to revolutionize pathology by utilizing fast tissue-to-digital imaging technology to replace analogue slide-based procedures with a smooth and efficient workflow that gives pathologists access to high-resolution digital tissue pictures without requiring the destructive preparation of direct-to-digital samples.

The FDA (Food and Drug Administration) has not reviewed the claims made about the SmartPath Imager. At this time, the SmartPath System is solely meant to be used for study. The FDA has not yet reviewed or approved this medical device. FDA-approved study has not demonstrated or validated its efficacy or safety. As of right now, SmartPath is not a medical equipment or diagnostic tool for human pathology that may be purchased in the US. This content is just meant to be informative and should not be used in place of expert medical advice. Furthermore, it is not an offer to market the gadget for any kind of medical application.